EGFR and lung carcinoma: In the present study, we examined whether the clinically approved mTOR inhibitors, temsirolimus and everolimus, circumvent HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer cells using in vitro and in vivo models, and assessed underlying mechanisms.